The Week Ahead: Fed...
Health Care: Drugs
Arrowhead Research Corporation (ARWR: NASDAQ)
$3.85 -0.08 | -2.04%
06/04/12 - 10:57 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.93 |
| 52 Week High | 11.90 |
| 52 Week Low | 3.12 |
| Avg. Daily Vol. (Mil) | 0.02 |
| Beta (3 year) | 2.74 |
| Share Related Items | |
| Mkt Cap (Mil) | 44.07 |
| Shares Out (Mil) | 11.21 |
| Float (Mil) | 10.43 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.30 |
| Current Ratio | 1.40 |
| LT Debt/ Equity | 0.17 |
| Total Debt / Equity | 0.19 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 798.20 |
| Price/Book | 3.60 |
| Price/Cash Flow | -3.60 |
| Per Share Data | |
| Earnings | -1.45 |
| Sales | 0.00 |
| Book Value | 1.09 |
| Cash Flow | -1.09 |
| Business Summary | |
|---|---|
| Arrowhead Research Corporation is a development stage nanotechnology holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies. | |
| General Information | |
| 201 South Lake Avenue
Suite 703 Pasedena, CA 91101 |
|
| www.arrowheadresearch.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 57 | |
| CEO: Dr. Christopher Anzalone | |
| Short Interest | |
| Current Month (Mil) | 0.28 |
| Previous Month (Mil) | 0.28 |
| Short Interest Ratio (Days) | 12.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -65.90 |
| Return on Investments | -92.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ARWR
- Portfolio NameUser Type
- UserKJP 2012 Carbon Flash Fund
- Contributor8 Penny Stocks Get Delistin...
- UserWilliam T Blanchard - Medical
- UserCaroline
- UserSimon $9000
- Usertreneehill's pennies
- Userpeaka22 Portfolio 1
- Userkevin sweeney Portfolio 1
- UserWORLD FREE
- Userkeyon communications
Latest ARWR Headlines from TheStreet
- Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript) 05.08.12 | 12:05 am
- 6 Stocks Hitting New 52-Week Highs 11.10.11 | 01:11 pm
- 8 Penny Stocks Get Delisting Warning 01.04.11 | 07:01 am
- Arrowhead Research CEO Discusses F4Q2010 Results  Earnings Call Transcript 12.22.10 | 09:12 pm
- Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript 08.12.10 | 06:08 pm
- Mediacom, Jones Soda: Midday Volume Plays 06.01.10 | 10:06 am
- Arrowhead Research, Verenium: Early Volume Plays 03.22.10 | 07:03 am
- Amicas, Limelight: Early Volume Plays 12.28.09 | 07:12 am
- Thursday's Small-Cap Winners & Losers 06.20.07 | 01:06 am
- Friday's ETF Winners & Losers 06.20.07 | 01:06 am
Press Releases for ARWR
- Arrowhead Presents Data On DPC System At TIDES 2012 - Business Wire 05.22.12 | 07:05 am
- Arrowhead Reports Fiscal 2012 Second Quarter Financial Results - Business Wire 05.08.12 | 04:05 pm
- Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides - Business Wire 04.11.12 | 07:04 am
- Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment - Business Wire 03.07.12 | 07:03 am
- Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics - Business Wire 03.05.12 | 07:03 am
- Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1) - Business Wire 02.29.12 | 07:02 am
- Arrowhead Reports Fiscal 2012 First Quarter Financial Results - Business Wire 02.09.12 | 04:02 pm
- Arrowhead To Report Fiscal 2012 First Quarter Financial Results - Business Wire 02.02.12 | 07:02 am
- Alnylam And Arrowhead Form Collaboration And Licensing Agreement - Business Wire 01.05.12 | 08:01 am
- Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial - Business Wire 01.04.12 | 07:01 am
Partner Headlines for ARWR
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Arrowhead Reports Q1 EPS of $(0.02) - Benzinga 02.10.11 | 04:02 pm
- UPDATE 1-Arrowhead co, Smith & Nephew to make cartilage product - Reuters 10.18.10 | 08:10 am
